Search
for
Sort by
Research 271–300 of 581
- Selective Janus kinase 1 inhibition resolves inflammation and restores hair growth offering a viable treatment option for alopecia areata
- A phase 2a trial of brepocitinib for cicatricial alopecia
- Case report: Psoriasiform eczema with immune-mediated comorbidities treated with upadacitinib
- Abrocitinib Improved Dupilumab-Resistant Severe Atopic Dermatitis with Comorbid Mild Alopecia Areata in a 12-Year-Old Boy: A Case Report with 1-Year Follow-Up
- 705 Particulate matter induces inflammatory response in human outer root sheath cells via oxidative stress-dependent MAPK and JAK-STAT signaling pathways
- A Subset of TREM2+ Dermal Macrophages Secretes Oncostatin M to Maintain Hair Follicle Stem Cell Quiescence and Inhibit Hair Growth
- Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients
- Targeted immunotherapy for hair regrowth and regeneration
- Predominant expression of interleukin (IL)‐17 in chronic alopecia areata compared to IFN‐γ in pathogenic Th17 cells, tissue‐resident memory T cells and natural killer cells
- Challenges, Progress, and Prospects of Developing Therapies to Treat Autoimmune Diseases
- Chemistry42: An AI-Driven Platform for Molecular Design and Optimization
- Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells
- Ruxolitinib protects skin stem cells and maintains skin homeostasis in murine graft-versus-host disease
- Primary cicatricial alopecias are characterized by dysregulation of shared gene expression pathways
- Understanding the Role of Type I Interferons in Cutaneous Lupus and Dermatomyositis: Toward Better Therapeutics
- Game Changers: Blockbuster Small-Molecule Drugs Approved by the FDA in 2024
- Protein degradation: expanding the toolbox to restrain cancer drug resistance
- Biliary fibrosis is an important but neglected pathological feature in hepatobiliary disorders: from molecular mechanisms to clinical implications
- Multi-omics analyses, cell experiments, and network pharmacology tools identified key proteins and candidate drugs for alopecia areata treatment
- Growth Hormone and the Human Hair Follicle
- Extensive alopecia areata is reversed by IL-12/IL-23p40 cytokine antagonism
- Ritlecitinib in severe alopecia areata: a profile of its use
- Case Series and Literature Review on Tofacitinib for Treating Severe Alopecia Areata
- Effect of tofacitinib on the expression of noggin/BMP-4 and hair growth stimulation in mice
- Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
- Effects of the RV3466F lotion on female telogen effluvium: Results from a 16 week, multi-centric, controlled, randomized trial
- Efficacy of tofacitinib in treatment of alopecia universalis in two patients
- Prolactin: an emerging force along the cutaneous–endocrine axis
- Serum level of interleukin-15 in active alopecia areata patients and its relation to age, sex, and disease severity
- MSC-EVs and UCB-EVs promote skin wound healing and spatial transcriptome analysis